PCM
BCRX icon

Polymer Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Polymer Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,353
Closed -$203K – 655
2026
Q1 		$203K Buy
+21,353
New +$166K 0.02% 740
2025
Q4 		– Sell
-18,325
Closed -$139K – 774
2025
Q3 		$139K Sell
18,325
-4,228
-19% -$35.2K 0.01% 718
2025
Q2 		$202K Sell
22,553
-6,737
-23% -$62.7K 0.02% 540
2025
Q1 		$220K Buy
+29,290
New +$236K 0.06% 424

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Polymer Capital Management's BCRX Position: Q2 2026 in Review

Polymer Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 21,353 shares — an estimated $203K sold.

Polymer Capital Management first reported a position in BCRX in Q1 2025 and held it in 4 quarters. The position peaked at $220K in Q1 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Polymer Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Polymer Capital Management sold 21,353 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $203K.
  • Polymer Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Polymer Capital Management's BioCryst Pharmaceuticals position peaked at $220K in Q1 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Polymer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.